Pharma Penny Stock Under Rs 55 In Focus as Company Bags International Order of USD 1,781,000
DSIJ Intelligence-1 / 07 Oct 2025/ Categories: Penny Stocks, Trending

The stock is up by 48.6 per cent from its 52-week low of Rs 35 per share.
Medico Remedies Ltd has successfully bagged a significant international government supply order valued at approximately USD 1,781,000 (One million seven hundred eighty-one thousand dollars) from The Main Pharmacy Association of the Ministry of Health and Medical Industry of Turkmenistan. This regulatory body is responsible for the centralised purchase and distribution of essential medicines for Turkmenistan's public health sector. The order requires Medico Remedies Ltd to supply a range of products, including tablets, capsules and dry syrups and the company is committed to completing the full supply in the shortest possible time. This supply contract represents a notable international engagement for Medico Remedies Ltd, reinforcing its presence in the global pharmaceutical supply chain.
Medico Remedies Ltd, established in 1994, is an Indian pharmaceutical company engaged in the manufacturing and marketing of a diverse range of pharmaceutical formulations. Their product portfolio includes various therapeutic segments such as antibiotics, anti-infectives, beta-lactam penicillin, cephalosporin, antifungals, antimalarials, antiretrovirals, anti-ulcer drugs and antacids, vitamins & supplements, hematinics and other drugs like NSAIDs, antihistaminics, anti-diabetics and cardiovascular drugs. The company operates a manufacturing facility in Palghar with a significant installed capacity for producing tablets (approximately 122.6 million units per month), capsules (around 36 million units per month) and dry syrup (about 0.12 metric tons per month).
The company has a market cap of Rs 428 crore. The stock is up by 48.6 per cent from its 52-week low of Rs 35 per share. The shares of the company have a PE of 40x, an ROE of 18 per cent and an ROCE of 21 per cent.
Disclaimer: The article is for informational purposes only and not investment advice.